论文部分内容阅读
以５１例晚期肿瘤患者作为研究对象，对其不同来源的肿瘤浸润淋巴细胞（ＴＩＬ）进行治疗研究，发现肿瘤组织来源的ＴＩＬ其有效率及一年生存率明显高于胸腹水及转移淋巴结的ＴＡＬ；其中肿瘤组织的ＴＩＬ，胸腹水、转移淋巴结的ＴＡＬ有效率分别为８０．９％、４０．０％、４６．６％；三者治疗肿瘤患者的一年生存率分别为８１．０％、４６．７％、６０．０％；另外发现胸腹水ＴＡＬ对实质性肿块治疗疗效较低，为４０％，其中静脉滴注更差，为１４．２％，而介入注射与局部治疗较好，为６２．５％；胸腹水ＴＡＬ对癌性胸腹水有一定疗效，以胸腹腔注射为最佳注射途径，消退率为７４％，高于静脉滴注２８．５％；对胸腹水治疗后不消退者进行分析，可能与肿瘤患者的病情有关，影响了ＴＡＬ的吸收。提示治疗实质性肿瘤以ＴＩＬ效果较佳，而ＴＡＬ对胸腹水有一定疗效，且以胸腹腔注射为最佳治疗途径。
51 cases of advanced cancer patients as the research object, its different sources of tumor infiltrating lymphocytes (TIL) for the treatment of tumor tissue-derived TIL found that its effective rate and one-year survival rate was significantly higher than the pleural effusion and metastatic lymph nodes TAL The effective rates of TAL, pleural effusion, ascites and metastatic lymph nodes were 80.9%, 40.0% and 46.6%, respectively. The one-year survival rates of the three tumor-bearing patients were 81.0% 46.7% and 60.0% respectively. In addition, TAL of pleural effusion and ascites was found to be 40% less effective in the treatment of solid tumors, of which intravenous instillation was even worse, 14.2%, while interventional injection and local treatment were better, Was 62.5%; hydrothorax ascites TAL on cancer pleural effusion have a certain effect, intra-abdominal injection as the best injection route, the regression rate was 74%, higher than the intravenous infusion of 28.5%; after treatment of pleural effusion and ascites Adiponectants for analysis, may be related to the condition of cancer patients, affecting the absorption of TAL. Tip TIL treatment of solid tumors better, and TAL pleural effusion have a certain effect, and to the thoracic and abdominal injection for the best treatment.